Abviva receives Japanese patent for Mammastatin Serum Assay Abviva.

SOURCE Abviva, Inc.. Abviva receives Japanese patent for Mammastatin Serum Assay Abviva, Inc. , a biomedical business engaged in the commercialization and development of breast malignancy related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology which may be utilized for therapeutic applications and in the Company’s breast cancer risk evaluation check, the Mammastatin Serum Assay . The patents are the most recent of 13 international and U.S. Patents to concern to the University of Michigan for breast cancers diagnostic and therapeutic uses of Mammastatin.Create and promote specialty programs in biotechnology entrepreneurship and administration. Promote credibility of domestic firms to the international community by enforcing uniform financial reporting, a transparent regulatory regime and reasonable business practices. Enact timely legislation and rules to nurture scientific and economic development. Stimulate rapid advancement of the IP infrastructure through educational and exchange programs. Strengthen wellness systems infrastructure and distribution mechanisms in concert with the development of the market to ensure that innovative health biotech products are available to the entire domestic population.. AORN helps Pennsylvania’s signing of HB 1641 requiring perioperative RN during surgery As advocates for individual safety in the operating room, the Association of periOperative Registered Nurses, , declared support for Pennsylvania Governor Ed Rendell’s signing of HB 1641 requiring the presence of a circulating nurse using operating rooms.